TY - JOUR
T1 - Filament-based 3D-printing of placebo dosage forms using brittle lipid-based excipients
AU - Abdelhamid, Moaaz
AU - Koutsamanis, Ioannis
AU - Corzo, Carolina
AU - Maisriemler, Mira
AU - Ocampo, Ana Belén
AU - Slama, Eyke
AU - Alva, Carolina
AU - Lochmann, Dirk
AU - Reyer, Sebastian
AU - Freichel, Tanja
AU - Salar-Behzadi, Sharareh
AU - Spoerk, Martin
N1 - Funding Information:
The Research Center Pharmaceutical Engineering (RCPE) is funded within the framework of COMET - Competence Centers for Excellent Technologies by BMK, BMDW, Land Steiermark and SFG. The COMET program is managed by the FFG. The authors would like to thank Aygün Dogan for his assistance during the extrusion process and extrudates characterization.
Publisher Copyright:
© 2022 Elsevier B.V.
PY - 2022/8/25
Y1 - 2022/8/25
N2 - In order to expand the limited portfolio of available polymer-based excipients for fabricating three-dimensional (3D) printed pharmaceutical products, Lipid-based excipients (LBEs) have yet to be thoroughly investigated. The technical obstacle of LBEs application is, however their crystalline nature that renders them very brittle and challenging for processing via 3D-printing. In this work, we evaluated the functionality of LBEs for filament-based 3D-printing of oral dosage forms. Polyglycerol partial ester of palmitic acid and polyethylene glycols monostearate were selected as LBEs, based on their chemical structure, possessing polar groups for providing hydrogen-bonding sites. A fundamental understanding of structure–function relationship was built to screen the critical material attributes relevant for both extrusion and 3D-printing processes. The thermal behavior of lipids, including the degree of their supercooling, was the critical attribute for their processing. The extrudability of materials was improved through different feeding approaches, including the common powder feeding and a devised liquid feeding setup. Liquid feeding was found to be more efficient, allowing the production of filaments with high flexibility and improved printability. Filaments with superior performance were produced using polyglycerol ester of palmitic acid. In-house designed modifications of the utilized 3D-printer were essential for a flawless processing of the filaments.
AB - In order to expand the limited portfolio of available polymer-based excipients for fabricating three-dimensional (3D) printed pharmaceutical products, Lipid-based excipients (LBEs) have yet to be thoroughly investigated. The technical obstacle of LBEs application is, however their crystalline nature that renders them very brittle and challenging for processing via 3D-printing. In this work, we evaluated the functionality of LBEs for filament-based 3D-printing of oral dosage forms. Polyglycerol partial ester of palmitic acid and polyethylene glycols monostearate were selected as LBEs, based on their chemical structure, possessing polar groups for providing hydrogen-bonding sites. A fundamental understanding of structure–function relationship was built to screen the critical material attributes relevant for both extrusion and 3D-printing processes. The thermal behavior of lipids, including the degree of their supercooling, was the critical attribute for their processing. The extrudability of materials was improved through different feeding approaches, including the common powder feeding and a devised liquid feeding setup. Liquid feeding was found to be more efficient, allowing the production of filaments with high flexibility and improved printability. Filaments with superior performance were produced using polyglycerol ester of palmitic acid. In-house designed modifications of the utilized 3D-printer were essential for a flawless processing of the filaments.
KW - filament-based 3D printing
KW - Lipid-based excipients
KW - Pharmaceutical dosage form
KW - Polyglycerol esters of fatty acids
KW - Solid lipid extrusion
KW - Sustainable manufacturing
UR - http://www.scopus.com/inward/record.url?scp=85134577228&partnerID=8YFLogxK
U2 - 10.1016/j.ijpharm.2022.122013
DO - 10.1016/j.ijpharm.2022.122013
M3 - Article
C2 - 35839981
AN - SCOPUS:85134577228
SN - 0378-5173
VL - 624
JO - International Journal of Pharmaceutics
JF - International Journal of Pharmaceutics
M1 - 122013
ER -